ERBB2 and neoplasm: Recent clinical observations have demonstrated that combining trastuzumab and pertuzumab together yields surprisingly synergistic results in tumour inhibition (that is, the combined effect of using the two molecules was far greater in effect than when using either alone) during the treatment of Her2 positive breast cancers that progressed during prior trastuzumab therapy [12].